Pfizer announces results of third-dose study: 'Higher antibodies against Delta variant'
Third dose of vaccine, Pfizer and BioNTech submit data to FDA: the two companies announce that the results of the phase 1 trial will also be submitted to the European Medicines Agency Ema in the coming weeks
